CSWC Earnings

CSWC reported its FY2026Q3 earnings on 2026-02-02, showcasing a revenue of 0.00 against an estimate of 58.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.63 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CSWC's FY2026Q3 earnings announcement on 2026-02-02, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, CSWC's stock price tends to shift by an average of +1.10% in the 10 days leading up to earnings and -1.37% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate CSWC’s annual revenue to reach 57.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.45% and EPS estimates Revise Downward by -0.1% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CSWC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.45%, while EPS estimates moved Revise Downward by -0.1% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CSWC's stock price typically moves by +1.10% in the 10 days before its earnings and -1.37% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 1.00 and revenue of 57.00M.

The company's earnings call summary and Q&A session highlight strong financial performance, strategic dividend changes, and a robust market strategy. Despite some slower growth in EBITDA and revenue, the company maintains a healthy outlook with diversified portfolios and conservative leverage. The transition to monthly dividends and potential legislative impacts are positive indicators. While there are concerns about healthcare investments and unclear guidance on some financial metrics, overall, the company's strategic initiatives and market activities suggest a positive outlook. Given the market cap, a 2% to 8% stock price increase is anticipated.